NEW YORK (GenomeWeb News) – Shares of Interleukin Genetics rose 16 percent in Thursday afternoon trade after the firm announced yesterday that the results of a retrospective study suggest that individuals who base their diet on genotype could potentially benefit from the firm's weight management genetic test.
The Waltham, Mass.-based genetic test maker said that a study conducted in collaboration with Stanford University researchers, who presented the study results and conclusions at an American Heart Association meeting taking place this week in San Francisco.
The study began in 2008 and has been assessing whether individuals who were assigned diets that were appropriate for their genotype could lose more weight than those who followed a diet inappropriate for their genotype, as determined by Interleukin's test. According to the firm, among the findings, individuals on genotype-appropriate diets lost 5.3 percent of body weight compared to individuals on diets not matched to their genotype, who experienced only 2.3 percent weight loss.
Interleukin also noted that the statistical significance of the findings increased when taking into account the actual diet habits reported by study participants.
"Results from this study are compelling and indicate strong potential for broad utility of a genetic test to guide diet and lifestyle choices," Interleukin Genetics Chief Scientific Officer Kenneth Kornman said in a statement.
In mid-afternoon trade Thursday on the American Stock Exchange, shares of Interleukin were up 16 percent at $1.42.